In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non-diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin-angiotensin-aldosterone system and sympathetic nervous systems results in 2 In the present review we document the increased incidence of HF, and the reasons for this increase, as well as its poor prognosis in patients with diabetes.
In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non-diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin-angiotensin-aldosterone system and sympathetic nervous systems results in cardiac remodelling, which worsens cardiac function. Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin-converting enzyme inhibitors and β-blockers. However, with HF with preserved ejection fraction (HFpEF), only therapy for the underlying risk factors helps.
Blockers of mineralocorticoid receptors may be beneficial in both HFrEF and HFpEF. Glucoselowering drugs can have a negative effect (insulin, sulphonylureas, dipeptidyl peptidase-4 inhibitors and thiazolidinediones), a neutral effect (α-glucosidase inhibitors and glucagon-like peptide-1 receptor agonists) or a positive effect (sodium-glucose co-transporter-2 inhibitors and metformin).
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| INTRODUCTION
Heart failure (HF) results from structural and/or functional impairment of ventricular filling and/or ejection 1 and it is a common and serious comorbidity of type 2 diabetes. 2 In the present review we document the increased incidence of HF, and the reasons for this increase, as well as its poor prognosis in patients with diabetes.
The potential therapies to both prevent and treat HF are discussed, in addition to the positive and negative effects of glucoselowering medications.
Several reviews on this important subject have been recently published [3] [4] [5] [6] [7] ; however, this is a rapidly evolving field. An important limitation has been that HF was not a primary endpoint in most cardiovascular (CV) outcome trials, and it has been the most heterogeneously distributed outcome.
| EPIDEMIOLOGY
As long ago as the Framingham Heart Study, HF was shown to be twice as common in men with diabetes and five times more common in women with diabetes between the ages of 45 and 74 years when compared with age-matched non-diabetic controls, and, in those aged ≤65 years, there was a fourfold increase in the prevalence of HF in men with diabetes and an eightfold increase in women with diabetes. 8 In almost 10 000 patients with type 2 diabetes enrolled in a Health Maintenance Organization, 12% had HF at entry. Independent risk factors for the presence of HF were older age, longer duration of diabetes, use of insulin and lower body mass index (BMI). 9 In addition, those with type 2 diabetes who did not have HF at entry developed HF at a rate of 3.3% per year. The Reykjavik Study reported a 12%
prevalence of HF in people with diabetes compared with 3% in people without diabetes in an Icelandic population study. 10 In the Zeeland A prospective study of 2737 elderly nursing home residents, free of HF, showed that after 43 months, 39% of those with diabetes compared with 23% of those without diabetes developed HF, a 30%
higher risk. 12 Diabetes is also associated with an elevated risk of hospital admission for HF (HAHF) of~33%. 13 Conversely, the presence of HF is an independent risk for developing type 2 diabetes. During a 3-year follow-up of HF patients without diabetes, 29% versus 18% of matched controls developed diabetes, and HF was shown to be an independent risk factor for developing diabetes. 14 patient-years. 16, 17 In studies in which patients had multiple CV risk factors and/or established CVD, the incidence ranged from 7.7 to 40.1 per 1000 patient-years. [18] [19] [20] [21] [22] With other aetiologies, such as chemotherapy-related toxicity, people with diabetes also had a higher incidence of HF. 23, 24 The regression of left ventricular hypertrophy (LVH) after aortic valve replacement has also been reported to be lower in patients with type 2 diabetes. 25 The dire prognosis of patients with diabetes with HF is well known. In the Swedish Heart Failure Registry, mortality was significantly increased by 37% if the patient had diabetes in addition to HF. 26 In older adults enrolled in the Medicare programme, those with diabetes and HF had a mortality of 32.7 per 1000 person-years compared with 3.7 per 1000 person-years among those without HF. 27 
| AETIOLOGY
Although epidemiological studies have shown a clear association between diabetes and HF, the pathophysiological explanation for this increase is less clear.
The coexistence of coronary artery disease (CAD), LVH and a specific diabetic cardiomyopathy, generally referred to as the cardiotoxic triad, leads to biochemical, anatomical and functional alterations in cardiomyocytes and cardiac tissues, and was originally thought to be the best explanation for the development of left ventricular dysfunction 2 ; however, the addition of fluid overload, which increases ventricular pressure in a stiffened ventricle, has also been proposed to extend the triad to the cardiotoxic tetrad ( Figure 1 ). 28 While severe coronary artery atherosclerosis is the expectation in patients with type 2 diabetes, there are patients with minimal or no coronary disease who develop HF, suggesting diabetic microangiopathy as an underlying aetiology. However, microvascular ischaemia has been excluded in these patients by the absence of increased lactate production during rapid atrial pacing. 29, 30 A more likely explanation for more distal obstruction, is that metabolic syndrome is associated with endothelial dysfunction leading to repeated episodes of vasoconstriction, reperfusion injury and myocardial dysfunction. 31, 32 Also associated with endothelial dysfunction is increased small vessel permeability, which can lead to interstitial oedema, fibrosis, myocardial ischaemia and LV dysfunction.
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There is also an increased prevalence of LVH in people with type 2 diabetes. In the Framingham and Framingham Offspring Studies using echocardiography, women but not men with diabetes had a ventricular mass that was 22% greater than their non-diabetic peers. 33 In the Scottish Tayside Study, again using echocardiography, LVH was present in 32% of normotensive people with type 2 diabetes independent of the presence of CAD, hypertension or the use of angiotensin-converting enzyme (ACE) inhibitors. 34 Of 371 people with type 2 diabetes who took part in a cross-sectional echocardiographic study in Scotland, 71%
had LVH, 41% had diastolic filling abnormalities and only 4.2% had systolic dysfunction. 35 Even paediatric patients with type 2 diabetes had a higher ventricular mass, mainly related to higher BMI and blood pressure. 36 In the DYDA study in people with type 2 diabetes, 23% had increased left ventricular mass unrelated to blood pressure levels but associated with components of metabolic syndrome (higher triglyceride levels and BMI). 37 LVH is therefore most likely associated with insulininduced cardiomyocyte growth attributable to metabolic syndrome. 38 A study in 1089 consecutive black patients who underwent both coronary angiography and M-mode echocardiography showed that LVH was an independent risk factor for mortality. With LVH there was a relative risk of death of 2.4 (95% CI 1.7-3.2) compared with multi-vessel CAD, 1.6 (95% CI 1.1-1.2), and relative risk of an ejection fraction of below 40% of 2.0 (95% CI 1.4-2.7). 39 Hypertension which occurs iñ 50% of people with diabetes further damages myocardial contractile proteins contributing to a hypertrophic state. 40 The high incidence of and poor prognosis from HF has been linked to the presence of an underlying diabetic cardiomyopathy, 41 characterized by myocardial fibrosis. Diabetic cardiomyopathy is also associated with depressed mechanical function, electrophysiological abnormalities, defects in sub-cellular organelles and catecholamine receptor downregulation as a result of elevated catecholamine changes in myocardial calcium transport and contractile proteins. 42, 43 The combination of ischaemic heart disease, LVH and diabetic cardiomyopathy in conjunction with an extracellular volume expansion, which may be resistant to the action of atrial natriuretic peptides, initially leads to diastolic dysfunction, which is very common in people 46 CKD is frequently observed in people with HF and glomerular filtration rate (GFR) has an inverse association with HF severity. The pathophysiology is bidirectional and includes chronic inflammation, activation of the renin-angiotensin-aldosterone system (RAAS), and haemodynamic changes. CKD is one of the major predictors of HAHF and CV mortality in such patients. 47 Metabolic syndrome also plays a major role in myocardial fibrosis.
With metabolic syndrome, there is an "overflow" of fat into many organs, including the heart. The presence of fat in the cardiomyocytes leads to higher myocardial free fatty acid levels, the metabolism of which leads to the production of toxic metabolites which, in turn, accelerate apoptosis, leading to myocardial fibrosis. In addition, the inflammation associated with metabolic syndrome plays a role in myocardial apoptosis. [48] [49] [50] The The cardiotoxic tetrad 28 stimulation of the RAAS. 53 Initially remodelling is adaptive and helpful for ventricular function, but eventually remodelling leads to progressive ventricular dysfunction.
Activation of the sympathetic nervous system results in the transcription of genes which were previously active in foetal life ("the foetal gene programme"). For example, atrial natriuretic peptide, which is only present in the atrium of the healthy heart, is re-expressed in the ventricle where it was present in foetal life. Also changed to a foetal pattern is the proportion of fast to slow isoforms of the myosin heavy chains. In addition, the alpha-actin gene, which is present only in skeletal muscle after birth, is re-expressed in the myocardium. Reexpression of these genes through suppression of ionotropic genes such as sarcoplasmic reticular Ca ++ ATPase (SERCA-2) results in decreases in both systolic and diastolic dysfunction, which initially may be an adaptive mechanism to protect the surviving myocardium through reduction of energy expenditure. 54 Beta blockade has been shown, at least in animals, to decrease the expression of SERCA-2 and other genes of the fetal gene programme, which is a maladaptation that compromises myocardial contractility. 55 Hormone deficiencies that are commonly associated with type 2 diabetes may also worsen HF. Testosterone deficiency is present in 25% of men with HF and testosterone level is proportional to the severity of the HF. Cardiac cachexia is associated with severely decreased testosterone levels, and intravenous replacement has been shown to increase the ejection fraction and decrease peripheral resistance as well as inflammation. Long-term testosterone use has also been shown to reduce myocardial fibrosis and improve exercise tolerance without increasing the ejection fraction 56, 57 ; however, long-term high-quality CV outcome studies of androgen therapy are not available and the benefits or harm of testosterone therapy in people with diabetes are far from settled.
Mainly as a result of obesity, vitamin D levels are lower in people with type 2 diabetes, and vitamin D deficiency has been shown to increase the rate of HAHF. 58 In an Italian prospective study of 19 092 men, vitamin D levels and HAHF were analysed. Those who were deficient (levels <10 ng/mL) had a significant 61% increase in HF compared with those who were vitamin D-sufficient (levels >30 ng/mL).
Even those with vitamin D levels between 10 and 29 ng/dL had a non-significant 48% increase in admission for HF; however, those results could simply be secondary to obesity associated with metabolic syndrome.
| DIAGNOSIS SCREENING AND THERAPY
At a routine office visit, patients with diabetes should be asked if they have symptoms of HF. Their exercise tolerance should be estimated by enquiring if the patient can climb more than one flight of stairs without having uncomfortable dyspnoea. Many patients with ventricular dysfunction do not report dyspnoea, 59 probably because of inactivity. Simply walking the patient in the clinic to assess time to dyspnoea may be helpful. 60 No matter how skilled the examiner may be, signs of HF may not be identified in people with HF. In the Studies of Left Ventricular Dysfunction (SOLVD) in people with an ejection fraction of <40%, one in three had rales, one in four oedema, one in four jugular venous distention and one in six a fourth heart sound. 61 To diagnose HF at the earliest time in people with diabetes, therefore, the use of a brain natriuretic peptide (BNP) plasma level or proBNP should be used. Plasma BNP has been shown to have a sensitivity of 92% and a specificity of 72%. 62 An abnormal BNP or proBNP screening should lead to an order for a two-dimensional and pulsed Doppler echocardiography to not only provide an ejection fraction but also to visualize the cardiac and structural changes that underlie HF. 63 Heart failure with preserved ejection fraction, that is, diastolic dysfunction, has been shown to be the cause of HF in~45% of patients with diabetes. 64 Unfortunately With a diagnosis of HFrEF in an individual with diabetes, suppression of the RAAS is efficacious. ACE inhibitors, by decreasing the conversion of angiotensin I to angiotensin II, reduce tissue and circulating levels of angiotensin II, which is not only a powerful vasoconstrictor but is also associated with overload-induced proliferative signalling.
Other benefits are achieved by elevating bradykinin and prostacyclin levels and are mediated through the release of nitric oxide. 68 Unlike ACE inhibitors, ARBs do not increase bradykinin levels and potentially may be less effective in the treatment of diabetic HF than ACE inhibitors. 69 ACE inhibitors have been shown to reduce mortality and limit morbidity in people with diabetes with HF through regression of myocardial remodelling. 70 Suppression of the sympathetic nervous system through beta blockade has been shown to be effective in reversing remodelling, especially in people with diabetes. 71 Activation of the sympathetic nervous system causes myocardial toxicity by altering gene expression, which, in turn, worsens myocardial remodelling. 72, 73 In people with metabolic syndrome, hyperinsulinaemia increases sympathetic tone. 74 High angiotensin II levels have a direct toxic effect on the myocardium, in addition to increasing sympathetic tone. 75 To prevent cardiac remodelling and improve HF both the sympathetic nervous system and the RAAS must be blocked. To achieve sympathetic blockade the β 1 , β 2 and α receptors should all be blocked.
First-generation β-blockers (propranolol and timolol) directly suppress the myocardium and are contraindicated in HF. Second-generation β-blockers (metoprolol and bisoprolol) are safe to use in HF but are of limited efficacy due to their selective β 1 (and not α and β 2 ) receptor blockade. Third-generation β-blockers (labetalol, nebivolol, carvedilol)
provide blockade of both β 1 , β 2 and α receptors. The most powerful member of this group is carvedilol, which, in addition to being a powerful anti-oxidant, selectively blocks α, β 1 and β 2 receptors, and has been shown in enhanced myocardial contractility to reverse remodelling and improve the ejection fraction in patients with HFrEF. 76 In clinical studies carvedilol causes an initial decrease in ejection fraction but, after 1 month, ventricular function improves so that at 3 months there is a significant improvement in the ejection fraction. After 18 months left ventricular mass significantly decreases and the remodelled spherical ventricle returns to its elliptical shape (reverse remodelling). 77 The increase in insulin resistance that occurs with most β-blockers does not occur with carvedilol and HbA1c decreases, insulin sensitivity improves and progression to microalbuminuria occurs less frequently 78 ; therefore, carvedilol should not be withheld in patients with diabetes.
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A more recent innovation in the treatment of diabetic HF is the use of a combination of sacubitril and valsartan. Sacubitril antagonizes the action of neprilysin, which degrades peptides including angiotensin and bradykinin. Sacubitril was developed as an anti-hypertensive but did not lower blood pressure because of a concurrent activation of the RAAS; however, when combined with the ARB valsartan, blood pressure was lowered and a decrease in HAHF was documented as well as decreases in both CV and total mortality compared to enalapril monotherapy. 80 In a post hoc analysis of this trial (PARADIGM-HF)
sacubitril/valsartan was shown in a diabetic population not only to lower HAHF and CV and total mortality, but also to significantly lower the HbA1c by 0.14% when compared with enalapril monotherapy. 81 In addition, initiation of insulin therapy was significantly lowered by 29% and the initiation of oral anti-hyperglycaemic therapy by 23%.
The mechanism of sacubitril/valsartan in improvement of glycaemic control is through lowering of insulin resistance.
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Drugs that are efficacious, therefore, in diabetic HFrEF are β-blockers, ACE inhibitors and the sacubitril/valsartan combination.
Digoxin is ineffective and all diuretics, except for spironolactone, simply improve symptoms without an improvement in cardiac function.
| EFFECT OF TREATING OBESITY AND EXERCISE IN PEOPLE WTH DIABETES AND HF
There is an association of obesity and HF. In a meta-analysis of 14 HF studies, participants were divided into five BMI groups and a Cox proportional hazards model was used to examine the independent association between BMI and 3-year total mortality. Analyses were conducted for the overall group as well as for HFrEF and HFpEF groups. Mortality in both HF subtypes showed a U-shaped curve, Through its anti-natriuretic effect, therefore, it is possible that insulin therapy could exacerbate HF.
| Sulphonylureas
Sulphonylureas (SUs) have been postulated to affect ischaemic preconditioning and coronary blood flow via their effect on the ATPsensitive K + channel; however, it is difficult to ascertain the importance of the channel subtype selectivity of various insulin secretagogues because of the lack of controlled studies addressing this. 105 Retrospective studies comparing the risk of HF with metformin and SUs suggest that use of SUs is associated with a higher risk of HF. In addition, in small studies, SUs have shown more CV events and higher in-hospital mortality after angioplasty for MI when compared with insulin, metformin or diet alone 106, 107 ; however, in the UKPDS, the mortality rate after an MI was the same whether the patients were taking SUs or not. 16 The Saskatchewan database showed an increased rate of HAHF with use of SUs when compared with the use of metformin, but after adjustments for history of ischaemic heart disease and use of ACE inhibitors or ARBs this was no longer statistically significant. 108 A possible explanation for the increased risk of HF with use of SUs is the increase in serum insulin levels; however, a more likely explanation is the ability of SUs to close ATP-sensitive K + channels.
While this closure is beneficial in the pancreatic β cell where it induces release of insulin, in the myocardium this could lead to negative effects, as noted previously. 111 This is in direct contrast to the effect of metformin, which increases the ATP levels in the cardiomyocytes (see below).
| Thiazolidinediones
The paradox of TZD treatment in HF is that, through volume expan- (95% CI 0.80-0.94) decrease in mortality and a 6% increase (95% CI 1.00-1.09) in readmission with HF. 122 Table 1 lists the studies that have assessed dipeptidyl peptidase-4 (DPP-4) inhibitor treatment for diabetes and the prevalance of HF.
| Dipeptidyl peptidase-4 inhibitors
Saxagliptin, while not increasing the number of cardiac events, was surprisingly shown in cardiac safety studies to be associated with an increased risk of HAHF (i.e. worsening HF), but not with CVspecific death.
In A meta-analysis of these three studies and smaller studies of DPP-4 inhibitors showed an overall statistically significant increase in HF of 16% (95% CI 1.01-1.33; P = 0.04). 127 Further meta-analyses showed an increase in HF in the range of 13% to 19%, which was statistically significant even when the data from SAVOR-TIMI were excluded. [128] [129] [130] By contrast, a recent network meta-analysis that included the three CV trials evaluating DPP-4 inhibitors (linagliptin not included) showed a neutral effect on incident HAHF (Relative Risk 1.11, 95% CI 0.95-1.30), with no significant between-study heterogeneity reported (I 2 = 42.2; P = 0.17). 4 The TECOS study 131 showed no increase in HAHF with the use of sitagliptin (HR 1.00, 95% CI 0.83-1.19). It has been postulated that the high use of metformin (81%) and low use of insulin (23%) and TZD treatment (2.7%) may account for this finding. Furthermore, during follow-up, insulin was initiated 30% more frequently in the placebo than in the sitagliptin group. Indeed, several observational retrospective population-based studies have shown an increased risk of HF, with use of sitagliptin ranging from 21% to 84% [132] [133] [134] ; thus, it is possible that sitagliptin may increase the incidence of HF unless it is protected by concurrent utilization of metformin. 135, 136 In the CARMELINA trial, however, which included people with type 2 diabetes at high risk of HF (concomitant atherosclerotic CVD and/or CKD), linagliptin did not affect the risk of HAHF among participants with and without a history of HF, regardless of previous left ventricular ejection fraction, which would not support the higher risk of HF being a class effect. Furthermore, 55% of the participants used metformin and 58% insulin, which could go against metformin having a protective role in this case. Abbreviations: CI, confidence interval; HAHF, hospital admission for heart failure; HF, heart failure; HR, hazard ratio.
the form of rice is a major part of the diet and, as a result, α-glucosidase inhibitors are more effective in lowering glucose levels.
A meta-analysis of seven placebo-controlled double-blind studies, 152 In a retrospective study of a large health system, medical records showed that GLP-1 receptor agonists reduced HAHF by 49% (95% CI 0.34-0.77; P = 0.02). 153 Based on these data, a prospective study of GLP-1 therapy for advanced HFrEF was performed. 154 Participants with HFrEF were randomized to the addition of subcutaneous liraglutide 1.8 mg daily or placebo. Liraglutide had no effect on mortality or readmission for HF in either the diabetes or the non-diabetes group. 155 Also, in the LEADER study, a large, randomized, blinded study with liraglutide, there was a non-significant 13% decrease (P = 0.14) in HAHF. 21 In the LIVE trial, which also included patients with chronic stable HF without diabetes, liraglutide did not affect systolic left ventricular function but was associated with an increase in serious cardiac adverse events, raising some concerns with respect to its use in patients with HFrEF. 156, 157 In the SUSTAIN-6 study, there was a 3.6% rate of HAHF with semaglutide compared with 3.3% for placebo (HR 1.11, 95% CI 0.77-1.61; P = 0.57). 158 In the EXSCEL study where once-weekly exenatide was compared with placebo for CV outcomes there was a 3.0% Metformin promotes AMP-activated protein kinase (AMPK) phosphorylation in the heart by increasing cytosolic AMP concentration, which promotes generation of ATP while at the same time decreases its utilization. 163, 164 After myocardial ischaemia and reperfusion, AMPK switches off ATP-consuming processes such as biosynthetic pathways while switching on catabolic processes that generate ATP-cellular uptake of glucose and fatty acids and increasing fatty acid oxidation. 165 Through this "fuel-gauge effect" metformin preserves myocardial mass and function, improving cardiac outcomes especially in people with diabetes and HF.
In a retrospective study of a large British database, metformin significantly decreased mortality by 28% compared with a 45% reduction with ACE inhibitor/ARB treatment and 24% with β-blocker treatment. 166 Medicare billing records of 16 417 patients discharged from hospital on metformin, compared with those discharged on an SU or insulin, showed a reduced mortality of 13% and readmissions of 8%. 122 In a retrospective study of patients with diabetes with low ventricular ejection fraction, metformin improved 1-year survival 167 ; therefore, through increased activity of AMPK, myocardial structure and function is maintained using metformin. 168 Metformin's effect on cardiac events and mortality in people with diabetes is probably attributable to its effect on cardiac failure. 169 A comprehensive search for controlled studies, evaluating the association between metformin and morbidity and mortality in people with diabetes mellitus and HF revealed nine cohort studies, but no randomized controlled trials. Metformin was associated with a 20% Table 3 shows the studies assessing sodium-glucose co-transporter-2 (SGLT2) receptor agonist treatment for diabetes and prevalence of HF.
| SGLT2 inhibitors
HAHF has been shown to be reduced with three different SGLT-2 inhibitors in three large prospective, randomized cardiac safety studies.
In the EMPA-Reg study empagliflozin decreased HAHF by 35% (95% CI 0.50-0.85; P = 0.002) 22 and in the CANVAS study HAHF was reduced by 33% (95% CI 0.52-0.87; P = 0.002). 171 In the DECLARE-TIMI 58 trial, the two primary efficacy analyses of dapagliflozin did not result in a higher or lower rate of major adverse cardiac events than pla- The reduction in HAHF with SGLT2 inhibitors is more pronounced than the effect on major adverse cardiac events, which is consistent with their effect on HF prevention and renal outcomes being more than that on atherosclerotic CV events. This is probably attributable to their renal mechanism of action leading to natriuresis and improved tubular glomerular feedback, reductions in blood pressure, arterial stiffness and improved endothelial function. In addition, weight loss and decrease in visceral adiposity and sympathetic activity may have a role 173 ; however, the two most likely aetiologies are a shift in fuel energetics and/or a diuretic effect. [174] [175] [176] A shift in fuel energetics away from fat and glucose oxidation, which are energy inefficient, in the setting of type 2 diabetes toward an energy-efficient super fuel like ketone bodies which increase myocardial efficiency and decrease cardiac workload is a plausible explanation.
Even small changes in ketone levels can result in major differences in cardiac efficiency and function as well as effecting outcomes. 174 A diuretic effect of SGLT2 inhibitors may be a more likely explanation. With SGLT2 inhibitors there is both an osmotic diuresis and natriuresis, both attributable to renal proximal tubule SGLT2 inhibition. However, this aetiology does not explain the decrease in HF, since if it did, thiazide and loop diuretics would result in more than symptomatic effects. In addition, the separation of the curves of hospital admission for HF occurs within 3 months, which has never been shown with a thiazide or loop diuretic but has been shown to occur with spironolactone. Acting through the Na To date, therefore, three SGLT-2 inhibitors have improved HF, probably through inhibition of the Na+/H+ exchange and/or through a shift in fuel energetics by increasing ketone production.
| CONCLUSION
As shown in Table 4 Abbreviations: CI, confidence interval; HAHF, hospital admission for heart failure; HF, heart failure; HR, hazard ratio. 
DPP-4 inhibitors
Drugs that have no effect on HF α-Glucosidase inhibitors
GLP-1 receptor agonists
Drugs that may prevent or ameliorate HF
Metformin

SGLT2 inhibitors
Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HF, heart failure; SGLT2, sodium-glucose co-transporter-2; SU, sulphonylurea; TZD, thiazolidinedione.
